GlassScriptPhysician profile
Matthew James Welch
NPI 1316100977
$15,575.80
in general payments reported to CMS, 2019-2025
20 companies · $359 in 2025
The $359 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,248 · 2020: $491 · 2021: $1,586 · 2022: $3,491 · 2023: $1,689 · 2024: $6,711 · 2025: $359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Acquisitions: $5,000 · Food and Beverage: $3,747 · Education: $12.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Acquisitions | $5,000.00 |
| Food and Beverage | $3,746.88 |
| Education | $12.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| US Retina LLC | $8,238.29 | 2019-2024 | |
| Alimera Sciences, INC. | $3,648.60 | 2022-2024 | Iluvien, Yutiq |
| Regeneron Healthcare Solutions, INC. | $964.43 | 2019-2025 | Eylea Hd, Eylea |
| Bausch & Lomb Americas INC. | $795.45 | 2022-2025 | Stellaris, Stellaris Elite, Xipere |
| Genentech USA, INC. | $406.26 | 2019-2025 | Vabysmo |
| Allergan, INC. | $297.00 | 2019-2021 | |
| Genentech, INC. | $219.74 | 2019-2023 | Susvimo, Vabysmo |
| Abbvie INC. | $186.79 | 2022-2025 | Ozurdex |
| Eyepoint US, INC. | $165.76 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $140.53 | 2019 | |
| Dutch Ophthalmic, USA | $130.58 | 2019 | |
| Apellis Pharmaceuticals, INC. | $82.34 | 2023-2024 | Syfovre |
| Coherus Oncology, INC. | $80.80 | 2022-2023 | |
| Alcon Vision LLC | $57.06 | 2022 | |
| Mallinckrodt Hospital Products INC. | $39.75 | 2023 | Acthar |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $33.11 | 2019 | |
| Mallinckrodt Enterprises LLC | $27.89 | 2019 | |
| Astellas Pharma US INC | $25.13 | 2023 | |
| Lumibird Medical INC. | $23.98 | 2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $12.31 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$44,293.36 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Welch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.